Eurobio Scientific UK delivers advanced molecular pathology and genomic profiling technologies designed to assist oncologists and pathologists with personalized cancer care. By looking beyond traditional tumor staging, our genomic selection systems provide deep prognostic insights to predict disease progression, safely evaluate recurrence risks, and map targeted therapy options.

Our primary focus features second-generation gene expression tests like the EndoPredict Breast Cancer Prognostic Test. These certified diagnostic tools evaluate tumor tissue samples directly to assist clinical multi-disciplinary teams in confidently deciding whether a patient will benefit from chemotherapy, reducing over-treatment while safeguarding individual patient health paths.